Phospholipid compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-12030904-B2
Application number	US-202318301179-A
Country	US
Kind code	B2
Filing date	Apr 14, 2023
Priority date	Aug 24, 2020
Publication date	Jul 9, 2024
Grant date	Jul 9, 2024

Abstract

Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

First claim

The invention claimed is:

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable slat thereof.

4. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical formulation comprising a pharmaceutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

9. The pharmaceutical formulation of claim 8 , wherein the pharmaceutical formulation is for oral administration.

10. A method of treating coronavirus infection in a human suffering therefrom, wherein the method comprises administering to the human the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

11. The method of claim 10 , wherein the coronavirus infection is a zoonotic coronavirus infection.

12. The method of claim 10 , wherein the coronavirus infection is a SARS-CoV-2 infection (COVID-19).

13. The method of claim 10 , wherein the coronavirus infection is a SARS virus infection.

14. The method of claim 10 , wherein the coronavirus infection is a MERS virus infection.

15. A method of treating pneumoviridae virus infection in a human suffering therefrom, wherein the method comprises administering to the human the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 , wherein the pneumoviridae virus infection is respiratory syncytial virus infection.

17. The method of claim 15 , wherein the pneumoviridae virus infection is human metapneumovirus infection.

18. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignees

• Gilead Sciences Inc

Inventors

• Lazerwith Scott E
• Medley Jonathan William
• Morganelli Philip A
• Naduthambi Devan
• Stratton Thomas P
• Wang Peiyuan

Classifications

• C07F9/6561 Primary

  containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings · CPC title

• A61P31/12

  Antivirals · CPC title

• A61K31/706

  containing six-membered rings with nitrogen as a ring hetero atom · CPC title

• C07H19/20 Primary

  with the saccharide radical esterified by phosphoric or polyphosphoric acids · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title